BRNS
Barinthus Biotherapeutics plc NASDAQ$0.64
Pre-mkt
$0.66
+4.47%
Mkt Cap $25.9M
52w Low $0.51
5.1% of range
52w High $2.92
50d MA $0.60
200d MA $0.93
P/E (TTM)
-0.4x
EV/EBITDA
0.6x
P/B
0.3x
Debt/Equity
0.1x
ROE
-89.5%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
-0.60
50d MA
$0.60
200d MA
$0.93
Avg Volume
40.2K
About
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a fu…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.28 | -0.14 | +50.0% | 0.65 | -3.1% | +0.1% | — | — | — | — | — |
| Mar 13, 2026 | AMC | -0.40 | -0.27 | +32.5% | 0.63 | +1.7% | +8.1% | +8.1% | +1.6% | +0.2% | +0.2% | — |
| Nov 7, 2025 | AMC | -0.45 | -0.36 | +20.0% | 1.07 | +0.9% | -17.8% | -25.2% | -24.4% | -26.9% | -25.7% | — |
| Aug 7, 2025 | AMC | -0.29 | -0.52 | -79.3% | 1.45 | -5.5% | -7.6% | -21.4% | -15.9% | -13.1% | -11.7% | — |
| May 7, 2025 | AMC | -0.34 | -0.49 | -44.1% | 0.99 | -5.1% | -9.1% | -12.4% | -6.0% | -8.1% | -10.1% | — |
| Mar 20, 2025 | AMC | -0.50 | -0.51 | -2.0% | 1.01 | -1.0% | -2.0% | +2.0% | +1.0% | +5.0% | +4.0% | — |
| Nov 6, 2024 | AMC | -0.45 | -0.21 | +53.3% | 1.48 | +0.0% | -0.7% | -8.8% | -7.4% | -5.4% | -5.4% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.43 | -2.4% | 1.38 | -1.4% | -2.2% | -2.9% | -4.3% | -4.3% | -5.8% | — |
| May 13, 2024 | AMC | -0.64 | -0.40 | +37.5% | 2.35 | -1.7% | -1.3% | -5.1% | +3.4% | +0.0% | +2.1% | — |
| Mar 20, 2024 | AMC | -0.55 | -0.45 | +18.2% | 2.45 | -0.4% | -1.6% | +5.3% | -1.6% | -2.0% | -4.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.80 | $0.80 | +0.6% | -3.2% | -10.3% | -8.2% | -12.4% | -10.1% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.01 | $1.00 | -1.0% | -2.0% | +2.0% | +1.0% | +5.0% | +4.0% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.04 | +1.0% | -8.7% | -8.0% | -1.0% | -1.9% | +1.0% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.84 | $0.88 | +4.9% | +6.1% | +7.4% | +18.1% | +6.9% | +16.4% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.47 | $1.52 | +3.4% | -8.2% | -6.8% | -4.8% | -4.8% | -6.1% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.19 | $1.20 | +0.8% | -0.8% | +0.8% | +4.2% | +11.8% | +5.9% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.20 | $1.24 | +3.3% | +0.0% | -1.7% | -0.8% | -1.7% | +0.0% |
| Aug 13 | Alliance Global Partners | Maintains | Buy → Buy | — | $1.34 | $1.41 | +5.2% | -1.5% | -1.5% | -3.0% | -6.7% | -5.2% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.35 | +0.0% | -0.7% | -2.2% | -2.2% | -3.7% | -7.4% |
| Jun 13 | Barclays | Maintains | Overweight → Overweight | — | $1.90 | $1.81 | -4.7% | +0.5% | -3.7% | -11.1% | -14.7% | -34.2% |
Recent Filings
8-K · 5.02
!!! Very High
Barinthus Biotherapeutics plc -- 8-K 5.02: Executive Change
Barinthus Biotherapeutics appointed Douglas Swirsky as Chief Financial Officer, a leadership change potentially signaling strategic financial direction for the biotech company's operations.
Apr 22
8-K
Barinthus Biotherapeutics plc -- 8-K Filing
Barinthus Biotherapeutics amended its merger agreement with Beacon on February 22, 2026, indicating modified deal terms that investors should review in full to understand potential impacts on the transaction completion and valuation.
Feb 23
Data updated apr 26, 2026 9:58am
· Source: massive.com